Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

Kate E. Stanley,Tatjana Jatsenko,Stefania Tuveri,Dhanya Sudhakaran,Lore Lannoo,Kristel Van Calsteren,Marie de Borre,Ilse Van Parijs,Leen Van Coillie,Kris Van Den Bogaert,Rodrigo De Almeida Toledo,Liesbeth Lenaerts,Sabine Tejpar,Kevin Punie,Laura Y. Rengifo,Peter Vandenberghe,Bernard Thienpont,Joris Robert Vermeesch

DOI: https://doi.org/10.1038/s41467-024-46435-0

IF: 16.6

2024-03-12

Nature Communications

Abstract:Abstract Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a limited number of bulk tissues or cell lines. Here, we utilize single cell transcriptome data as a comprehensive cellular reference set for disease-agnostic cfDNA cell-of-origin analysis. We correlate cfDNA-inferred nucleosome spacing with gene expression to rank the relative contribution of over 490 cell types to plasma cfDNA. In 744 healthy individuals and patients, we uncover cell type signatures in support of emerging disease paradigms in oncology and prenatal care. We train predictive models that can differentiate patients with colorectal cancer (84.7%), early-stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and preeclampsia (88.3%) from matched controls. Importantly, our approach performs well in ultra-low coverage cfDNA datasets and can be readily transferred to diverse clinical settings for the expansion of liquid biopsy.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to use the characteristics of circulating cell - free DNA (cfDNA) fragments to identify disease - related cell types, thereby providing new insights into disease biology. Specifically, by using single - cell transcriptome data as a reference set, the authors developed a new method to analyze the cellular origin of cfDNA. This method is able to:

1. **Identify the cell - type characteristics of cfDNA in the plasma of healthy individuals and patients**: By analyzing cfDNA fragment data at different coverages, the authors were able to infer the relative contributions of more than 490 cell types to plasma cfDNA.

2. **Explore the cell - type characteristics of multiple diseases**: In samples from 744 healthy individuals and patients, the authors discovered cell - type characteristics that support emerging disease patterns in oncology and prenatal care. These characteristics are helpful for understanding the molecular mechanisms of diseases.

3. **Construct prediction models to distinguish different types of diseases**: The authors trained prediction models that can effectively distinguish patients with colorectal cancer (84.7%), early - stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and pre - eclampsia (88.3%) from the control group.

4. **Enhance the clinical application value of ultra - low - coverage cfDNA data**: Research shows that even in ultra - low - coverage cfDNA datasets, this method can exhibit good performance, which enables it to be widely applied in different clinical scenarios and expands the application range of liquid biopsy.

Through the above methods, the paper aims to provide a new, non - invasive means to diagnose and monitor multiple diseases, especially cancer and pregnancy complications, thereby providing strong support for clinical practice.